Previous studies have shown that intravenous injection of OXT, which specifically binds to pathologically upregulated OXTR, can reduce the levels of inflammatory cytokines and alleviate AD pathological damage by blocking the ERK/p38 MAPK and COX‐2/iNOS NF‐κB signaling pathways [46]. This evidence concerns the gene OXT and Alzheimer disease.